Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative treatment modality for patients with myelofibrosis (MF). Earlier studies using myeloablative regimens have shown that approximately 35-45% of patients achieve long-term cure from MF. [1] [2] [3] The curative potential of alloHCT is related to a combination of the reduction or eradication of the malignant clone by the conditioning regimen and a graft-versus-MF effect. A major barrier to alloHCT using conventional intensity conditioning (CIC) regimens is the high TRM observed in 30-45% of patients, which restricts the use of the procedure to a limited number of young and fit patients. In the last decade, several studies have demonstrated the feasibility of non-myeloablative or reduced-intensity transplantation, collectively called reduced-intensity conditioning (RIC) regimens, in the management of MF. [4] [5] [6] [7] However, comparative data on the outcomes of CIC regimens to RIC regimens in patients with MF are scanty. 7 Owing to the low transplant activity for MF, it is difficult to conduct such studies. Even the large centers do only a few of these transplants every year. The majority of patients with MF are in the older age group and physicians may be hesitant to refer these patients to the transplant centers. It is not known whether patients undergoing RIC have a similar benefit from the transplant procedure as patients undergoing CIC. There is a concern that resolution of fibrosis may not be complete and there may be an increased risk of relapse in patients with MF with RIC when compared with CIC as seen in some of the hematological malignancies.
We analyzed the impact of conditioning intensity on the outcomes of alloHCT in MF. This multicenter retrospective study included 46 consecutive patients treated at three Canadian and four European transplant centers between January 1998 and December 2005. The diagnosis of MF was made on the basis of criteria published by Barosi et al. 8 Data on surviving patients were updated as of October 2007. This report includes 11 patients reported in earlier studies with extended follow-up. 6, 7 The indication for alloHCT was intermediate-or high-risk disease (according to the Dupriez Score) in 39 (85%) patients, whereas seven patients underwent transplant for low-risk disease because of constitutional symptoms (n ¼ 5) or recurrent thrombosis (n ¼ 2). Twenty-three patients received CIC and 23 received RIC. Of the 23 patients receiving CIC regimens, 22 received high-dose CY and low-dose TBI (200 cGY). GVHD prophylaxis in the two cohorts is summarized in Table 1 . A significantly higher proportion of patient in the RIC cohort received serotherapy with anti-thymocyte globulin or alemtuzumab. Engraftment, graft failure, severity of acute and chronic GVHD were defined according to previously published standard criteria. 9 PFS and overall survival were calculated from the transplant date by using the Kaplan-Meier method. The cumulative incidences were estimated for graft failure (primary and secondary), acute GVHD and chronic GVHD, whereas death from any cause was treated as a competing risk.
Baseline characteristics and transplant-related outcomes of the patients undergoing CIC and RIC are summarized in Tables 1 and 2 , respectively. No significant differences were found in the cumulative incidences of graft failure in the two study cohorts. Patients in whom the results of pre-BMT and a minimum of two post-BMT biopsies were available were considered evaluable for the assessment of regression of fibrosis. These data were available on 24 patients (CIC cohort, 14 (61%); RIC cohort, 10 (43%)) and no significant differences were observed in time to resolution of fibrosis. The groups did not differ in the cumulative incidence of relapse/progression. At a median follow-up of 50 (20-89) months for survivors, there was a trend toward better PFS or overall survival of patients transplanted with RIC regimens ( Table 2) .
The results of this study suggest that both types of conditioning regimens have curative potential in patients with MF. Patients receiving RIC were significantly older and tended to have longer disease duration and poorer performance status. In spite of these differences, a similar survival was observed for both study cohorts. One of the concerns using an RIC approach is the higher rate of disease relapse. This study did not reveal any significant difference in relapse/progression among recipients of CIC or RIC. An earlier study from the myeloproliferative disease research consortium using the RIC approach reported a relapse rate of 14% in 21 patients with MF. 4 Another multicenter study from Germany did not observe any cases of relapse in 21 patients with MF treated with RIC. 6 Similar data were obtained in a recent Swedish study in which the only patient out of 27 allografted who died of relapse had been transplanted using myeloablative conditioning. 7 The cumulative incidence of relapse was 29% in a recent report investigating the role of RIC in MF. 10 Taken together, reports in the literature and the observations in this study suggest that the relapse rate after alloHCT in MF is relatively low, also after RIC transplants. These observations are compatible with an immunological mechanism-'graft-versus-MF'-being effective at eliminating the malignant clone without myeloablative chemotherapy. In our study, the cumulative incidence of acute and chronic GVHD in the RIC cohort was significantly lower than that in the CIC group. These differences may not be related to intensity of conditioning alone, as serotherapy with anti-thymocyte globulin or alemtuzumab received by 70% of the patients in the RIC group may have contributed to the low frequency of GVHD. Table 2 Comparison of transplant-related outcomes for the patients undergoing allogeneic transplantation using conventional and reducedintensity conditioning One of the main shortcomings of this study is the small sample size limiting the ability to do a multivariate analysis to adjust for potential confounding factors. However, these data suggest that despite more adverse pre-transplant variables in the RIC cohort, the outcomes are not inferior. Our data indicate that the benefit of allografting using an RIC approach is similar to that using CIC. Therefore, older patients who are not eligible for CIC should not be denied the option of transplant if clinically indicated. An important question that remains unanswered is whether RIC should be offered to younger patients with MF in an attempt to decrease TRM. This question should preferably be answered by a formal randomized trial in younger patients with MF, comparing conventional and reducedintensity approaches. 
